Key Takeaways
Extended Takeaways
- The acute benefit was not evident at 8 weeks (P = .11), but was significant by 16 weeks, which supports setting expectations that adjunctive cognitive-behavioral therapy may require a full course before clear separation from usual medication management emerges.
- Functional and self-rated outcomes did not parallel the clinician-rated primary outcome: BDI-II, QIDS-SR, and SF-36 mental and physical subscales showed no statistically significant between-group differences at each time point, so clinicians may want to track both clinician-rated and patient-reported measures when judging progress.
- The response and remission data suggest a clinically meaningful yield from augmentation: at 16 weeks, treatment response was RR = 2.38; 95% CI, 1.48 to 3.84; NNT = 5; 95% CI, 3 to 83, and remission was RR = 2.13; 95% CI, 1.04 to 4.35; NNT = 5; 95% CI, 3 to 36.
- This was a relatively complex specialty-care sample rather than a mildly symptomatic outpatient group: 31 participants (38.6%) had received 3 or 4 courses of antidepressants, 19 (23.8%) had received 5 or more courses, 18 (22.5%) had a past history of psychiatric hospitalization, and 17 [21.3%] had previous suicide attempts.
- The intervention appears feasible to implement in psychiatric specialty care with modest session intensity: patients were offered 16 individual 50-minute sessions, medication visits in both groups occurred roughly every 2 weeks for 10-15 minutes, and there were no differences in antidepressant dose changes or number of medical visits during follow-up.
- The durability of effect strengthens confidence that the finding was not driven by short-term missing-data assumptions, because 73 (91.3%) were followed up for 12 months and pattern-mixture sensitivity analyses still showed between-group differences of −4.1 to −4.3 (P ≤ .02 for all) versus −4.4 (P = .002) in the primary model.
